RxDoctor Payments Data

Rebekah Lucero

Family · Pocatello, IDNPI 1285295634

Payments from drug & device makers

What this record shows

Medtronic accounts for 68.0% of it on its own, with 24 other manufacturers making up the rest. 2025 is the largest year on record at $5,217, more than ten times the $106 reported in 2022. Among family clinicians in ID with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$6,778in general payments, 2019–2025

Across 134 payments — averaging $50.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$5K
  • Pfizer$298
  • Novartis$285
  • AbbVie$213
  • Amgen$194
  • Lexicon Pharmaceuticals, Inc.$161
  • plus $1K from 19 others

What the payments were for

  • Travel & lodging$3,50352%
  • Food & beverage$3,27548%

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,778 in reported general payments places this provider in the 95th percentile of 809 family providers in Idaho.

See all family providers in Idaho

Medicare billing

Part B allowed, 2024
$41,930
Medicare patients
331
Services billed
591

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CamzyosMavacamten26$213,901
EliquisApixaban189$186,335
Repatha SureclickEvolocumab139$96,162
JardianceEmpagliflozin125$92,409
FarxigaDapagliflozin Propanediol96$84,194
EntrestoSacubitril/Valsartan91$81,796
XareltoRivaroxaban45$53,043
Praluent PenAlirocumab35$17,687
Ezetimibe334$5,378
Potassium Chloride181$4,413
Metoprolol Succinate402$4,293
Atorvastatin Calcium336$4,002
Amiodarone Hcl42$2,513
Diltiazem 24hr Er (Cd)Diltiazem Hcl43$2,272
Rosuvastatin Calcium184$1,928

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
E.r. Squibb & Sons, L.L.C.Camzyos$65$213,90126 claims
PfizerEliquis$298$186,335189 claims
Boehringer IngelheimJardiance$101$92,409125 claims
AstraZenecaFarxiga$15$84,19496 claims
NovartisEntresto$285$81,79691 claims
Johnson & JohnsonXarelto$43$53,04345 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 809 family providers in Idaho.

Other family in Pocatello

See the full list for Idaho

Where these figures come from

Is this you, or does something look wrong? →